SEINE BIO · PEPTIDE PROFILE

Mazdutide

Dual glucagon/GLP-1 agonist · international metabolic science

China-specific approval

Get to know the name, understand the evidence, and prepare a more informed conversation.

What is Mazdutide?

A dual glucagon/GLP-1 receptor agonist. Innovent announced NMPA approval for glycemic control in adults with type 2 diabetes in September 2025. China-specific authorization must not be presented as U.S. approval.

THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026

Inside the science of Mazdutide.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.

Overview

Mazdutide is a dual GLP-1 and glucagon receptor agonist studied in metabolic disease. Its development spans Chinese studies and a U.S. obesity trial, making the country and study population important to interpretation. A favorable overseas result is informative scientific evidence, but it is not by itself a U.S. prescription or importation pathway.

Community Use

PeptideDosages’ mazdutide page supplies a community calculation reference. No exact Peptidepedia.org mazdutide profile was verified for this draft. A publisher’s protocol cannot verify an online preparation or show that a regimen from one country’s clinical program is suitable for another person.

Doses, Durations & Cycles

Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.

Protocol reference — Mazdutide
Route / formulation	Dose / reported phases	Frequency	Duration / break	Notes and source
Subcutaneous	3/4.5 mg arms began at 1.5 mg; 6 mg arm began at 2 mg. Targets: 3, 4.5 or 6 mg; steps at 4-week intervals.	Weekly	24 weeks Break: No biohacking break established by this study	Controlled phase 2 study in China Nature Communications 2023: Chinese phase 2
Subcutaneous	Assigned targets 4 or 6 mg; initiation not established from the abstract reviewed	Weekly	48 weeks Break: No biohacking break established by this study	Controlled phase 3 study in China NEJM 2025: GLORY-1
Subcutaneous	Separate cohorts: 3 → 6 → 9 mg at 4-week intervals; or 2.5 → 5 → 7.5 → 10 mg at 4-week intervals	Weekly	9 mg cohort: 12 weeks; 10 mg cohort: 16 weeks Break: No biohacking break established by this study	Controlled phase 1b study eClinicalMedicine 2022: higher-dose cohorts
Subcutaneous	Separate target arms: 3-to-6, 10 or 16 mg; initiation details not established from the abstract reviewed	Weekly	48 weeks Break: No biohacking break established by this study	Controlled U.S. phase 2 study Lancet Diabetes & Endocrinology 2026: U.S. phase 2
See linked publisher; route not stated in audited excerpt	Community-reported range 3–9 mg weekly; 3 mg described as a common starting dose; chart also includes 1.5, 4.5 and 6 mg.	Weekly amounts reported	No fixed total course stated Break: Not stated	Published informal biohacking claim Peptide Protocol Wiki, Mazdutide calculator
See linked publisher; route not stated in audited excerpt	Website schedule: 3 mg weekly in weeks 1–4, 4.5 mg in weeks 5–8, 6 mg in weeks 9–12, then 9 mg every week.	Weekly amounts reported	No fixed total course stated Break: Not stated	Published informal biohacking claim OptimalDosages, Mazdutide

Important context: 3/6/9 mg are not validated universal starting/average/maximum doses. The 3-to-6-to-9 mg sequence belongs to one 12-week phase 1b cohort. Published human research includes doses above 9 mg.

Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.

The table identifies study-specific regimens separately from informal material. The Chinese diabetes trial studied weekly groups under controlled conditions; the U.S. phase 2 trial evaluated different exposures. These are not interchangeable dose menus, and neither supplies an unsupervised wellness cycle.

Research Findings

The Chinese phase 3 study randomized 320 adults with type 2 diabetes and evaluated HbA1c at 24 weeks. A separate U.S. phase 2 study enrolled adults with overweight or obesity without type 2 diabetes. Different disease backgrounds and endpoints mean the reports should be read separately rather than blended into one universal claim.

U.S. Approval & Access

Country-specific authorization and U.S. access are separate questions. The papers linked here do not establish that Seine Bio can supply mazdutide. Before considering any clinical or research pathway, the provider must check the exact product’s current authorization and the applicable program. Overseas approval cannot be assumed to permit ordinary U.S. importation or prescribing.

What It Does in the Body

The dual-agonist design combines GLP-1-related effects with glucagon-receptor activity. Researchers test how that balance affects glucose and body weight. It does not follow that every dual agonist behaves like tirzepatide, which has a different receptor pairing. Molecule-specific data are needed, including exposure and tolerability. Reliable onset, peak clinical benefit and duration after stopping are not established for routine care by the sources reviewed; the length of a trial is not the duration of a guaranteed effect.

Benefits & Reported Experiences

In the Chinese diabetes study, HbA1c and body weight improved compared with placebo over the defined treatment period. The U.S. obesity study addresses a different efficacy question. Those findings do not predict what an unofficial preparation will do. Compare the endpoint, duration and population before using results to judge a personal care option.

Side Effects & Risks

The clinical reports describe gastrointestinal adverse events, including diarrhea and reduced appetite. Safety observations remain specific to the manufactured study product and monitored participants. Cross-study comparisons should include treatment withdrawal and exposure, not only a claim of tolerability. Unverified materials introduce uncertainties the trials cannot quantify.

Delivery Options

The cited studies used subcutaneous investigational treatment. That fact supplies research context, not consumer administration instructions. If an appropriate legitimate program is available, its clinical team determines the product and monitoring. This article provides no vial preparation, injection tutorial or study-to-self-use dose conversion.

Product Quality & Storage

Confirm the named molecule, jurisdiction, formulation and program. Similar marketplace names do not establish identity or equivalence to a study medicine. Quality questions include lawful supply and accountability for adverse events, not just a laboratory purity number. Ask who actually supplies and oversees treatment rather than relying on promotional terminology. No verified patient-use storage specification is supplied by the cited research. Research materials cannot inherit an approved medicine’s stability or storage instructions; an authorized program must provide its product-specific conditions.

Combinations & Interactions

Mazdutide’s trials do not establish a combination with semaglutide, tirzepatide or additional research peptides. Receptor overlap is a reason to seek a clinical review, not a recipe for greater efficacy. This page supplies no stacking order or timing, and background diabetes medication must be evaluated within a complete care plan.

Talking With Your Provider

A consultation can review what the published work shows, whether any appropriate lawful program exists and which established choices can address your goal now. Bring your diabetes history, prior therapies and current medication list. An evidence-informed alternative may be more useful than waiting for access to a specific development molecule.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.

Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.

Questions worth bringing to your appointment.

Are there alternatives that address my goal?
If treatment is appropriate, what monitoring and follow-up would I need?
Could my health history or current medicines change the risks?

A clinician may recommend a different option—or no medication—after assessing your individual circumstances.

Saved discussion topics 0

Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.

Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.

Bring your curiosity. Start a conversation.

Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.

Create a free account ↗

This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.

Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.

Bring your saved topics to your care team.

Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.

Choose saved topics for review →